| Bioactivity | T3SS-IN-5 (Compound F9) is a specific inhibitor of the type III secretion system (T3SS). T3SS-IN-5 reduces bacterial pathogenicity without affecting bacterial viability by inhibiting the expression of genes associated with T3SS[1]. |
| Invitro | T3SS-IN-5 对 Xcc 的生存能力没有统计学上的显著影响[1]。T3SS-IN-5 (200 μM; 5 d) 使 Xcc-jx-6 诱导的 本氏烟草的过敏反应 (HR) 显著降低[1]。T3SS-IN-5 (200 μM; 4-7 d) 减轻了奥拉赫橙的溃疡症状，在同等浓度下效果比 bismerthiazol 更明显[1]。T3SS-IN-5 (200 μM; 16 h) 处理后，Xcc 的相对发病率显著降低[1]。T3SS-IN-5 (200 μM; 48 h-5 d) 不影响 Xcc 其他毒力因子，包括胞外酶活性、EPS活性、运动性和生物膜形成[1]。T3SS-IN-5 (100-200 μM; 4 d) 和 Burkholderia anthina hN-8 联合使用进一步改善了对 Xcc 的抑制作用[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> T3SS-IN-5 相关抗体: RT-PCR[1] Cell Line: |
| Formula | C16H14N2OS2 |
| Molar Mass | 314.43 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Zhang YQ, et al. Design and Synthesis of Mandelic Acid Derivatives for Suppression of Virulence via T3SS against Citrus Canker. J Agric Food Chem. 2024 May 1;72(17):9611-9620. |